CD
ABBV icon

Chapin Davis’s AbbVie ABBV Stock Holding History

Chapin Davis’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
15,763
+1,500
+11% +$323K 0.7% 31
2026
Q1 		$3.1M Buy
14,263
+847
+6% +$188K 0.69% 32
2025
Q4 		$3.07M Sell
13,416
-52
-0.4% -$11.8K 0.72% 35
2025
Q3 		$3.12M Buy
13,468
+462
+4% +$94.1K 0.77% 30
2025
Q2 		$2.41M Buy
13,006
+1,487
+13% +$276K 0.67% 35
2025
Q1 		$2.41M Buy
11,519
+1,892
+20% +$368K 0.82% 25
2024
Q4 		$1.9M Hold
9,627
– – 0.62% 37
2024
Q3 		$1.9M Buy
9,627
+215
+2% +$40.1K 0.62% 38
2024
Q2 		$1.61M Buy
9,412
+340
+4% +$56.3K 0.55% 42
2024
Q1 		$1.65M Sell
9,072
-2,400
-21% -$414K 0.6% 35
2023
Q4 		$1.78M Buy
11,472
+1,125
+11% +$164K 0.75% 31
2023
Q3 		$1.54M Sell
10,347
-739
-7% -$108K 0.74% 33
2023
Q2 		$1.49M Buy
11,086
+43
+0.4% +$6.31K 0.71% 32
2023
Q1 		$1.76M Buy
11,043
+179
+2% +$27.4K 0.91% 25
2022
Q4 		$1.76M Buy
+10,864
New +$1.67M 1.02% 26

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Chapin Davis's ABBV Position: Q2 2026 in Review

Chapin Davis increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $323K and bringing the position to 15,763 shares worth $3.97M. The position accounts for 0.7% of the portfolio, ranked #31.

Chapin Davis first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Chapin Davis held 15,763 shares of AbbVie worth $3.97M as of Q2 2026.
  • Chapin Davis bought 1,500 AbbVie shares in Q2 2026, an estimated $323K.
  • AbbVie made up 0.7% of Chapin Davis's portfolio in Q2 2026, its #31 holding.
  • Chapin Davis first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.